Clinical impact of EGFR mutation fraction and tumor cellularity in EGFR mutation positive NSCLC.
Petra Martin
No relevant relationships to disclose
Carolyn Jane Shiau
No relevant relationships to disclose
Maria D Pasic
No relevant relationships to disclose
Ming Sound Tsao
No relevant relationships to disclose
Suzanne Kamel-Reid
No relevant relationships to disclose
Lisa Le
No relevant relationships to disclose
Brian Patrick Higgins
No relevant relationships to disclose
Susanna Y. Cheng
No relevant relationships to disclose
Ronald L. Burkes
No relevant relationships to disclose
Matilda Ng
No relevant relationships to disclose
Saroosh Arif
No relevant relationships to disclose
Tudor Roxana
No relevant relationships to disclose
Stephanie Chen Xing Lin
No relevant relationships to disclose
Peter Michael Ellis
No relevant relationships to disclose
Stacey Hubay
No relevant relationships to disclose
Sara Kuruvilla
No relevant relationships to disclose
Scott Andrew Laurie
No relevant relationships to disclose
Jing Li
No relevant relationships to disclose
Frances A. Shepherd
Consultant or Advisory Role - AstraZeneca; Biodesix; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck; Recombio; Roche
Stock Ownership - Lilly; Pfizer
Honoraria - GlaxoSmithKline; Lilly; Roche
Expert Testimony - AstraZeneca
Natasha B. Leighl
No relevant relationships to disclose